Physician profile
Chad E Wagoner
NPI 1871582130
$17,123.67
in general payments reported to CMS, 2019-2025
58 companies · $2,549 in 2025
The $2,549 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,915 · 2020: $1,390 · 2021: $2,918 · 2022: $2,593 · 2023: $2,842 · 2024: $2,916 · 2025: $2,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,307 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,306.54 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,439.88 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,518.32 | 2021-2025 | Vraylar, Linzess, Creon |
| Lilly USA, LLC | $1,391.00 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $1,293.03 | 2019-2025 | |
| Novo Nordisk INC | $1,141.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,022.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $861.47 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $767.40 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $743.59 | 2019-2024 | Otezla, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $649.01 | 2019-2025 | Xarelto, Spravato |
| Abbott Laboratories | $626.03 | 2021-2025 | Freestyle Libre |
| Astellas Pharma US INC | $480.23 | 2019-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $467.07 | 2019-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $339.90 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $330.14 | 2019-2024 | Verquvo, Belsomra, Dificid |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Wagoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.